Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Tabea SutterMarcus SchittenhelmThomas VolkenThomas LehmannPublished in: Hematology (Amsterdam, Netherlands) (2023)
Abbreviations: AML, acute myeloid leukaemia; BCL2, B-cell leukaemia/lymphoma-2; BSC, best supportive care; CR, complete response; Cri, complete response with incomplete haematologic regeneration; FLT3, Fms Related Receptor Tyrosine Kinase 3; EKOS, Ethikkomission Ostschweiz; ELN, European Leukaemia Net; HMA, hypomethylating agent; IC, intensive chemotherapy; IDH, Isocitratdehydrogenase; LDAC, low-dose Cytarabine; NCCN, National Comprehensive Cancer Network; OS, overall survival; PC, platelet concentrate; RBC, red blood cell; RCT, randomized controlled trials; t-AML, therapy relative acute myeloid leukaemia'; VEN, venetoclax.
Keyphrases
- acute myeloid leukemia
- tyrosine kinase
- liver failure
- red blood cell
- low dose
- respiratory failure
- epidermal growth factor receptor
- drug induced
- bone marrow
- allogeneic hematopoietic stem cell transplantation
- dendritic cells
- randomized controlled trial
- aortic dissection
- stem cells
- end stage renal disease
- quality improvement
- healthcare
- palliative care
- hepatitis b virus
- diffuse large b cell lymphoma
- low grade
- pain management
- immune response
- patient reported outcomes
- affordable care act